Scientist, Predictive Biology and AI at Bristol-Myers Squibb

Seattle, Washington, United States

Apply Now

Not SpecifiedCompensation

Mid-level (3 to 4 years), Senior (5 to 8 years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, Pharmaceutical, Oncology, NeuroscienceIndustries

Requirements

Bachelor's Degree with 5+ years of academic/industry experience, or Master's Degree with 3+ years of academic/industry experience, or PhD (no experience required)
Preferred: Ph.D. with 0+ years industry research experience or M.S. with 3+ years industry research experience in computer science, statistics, computational biology, or another quantitative field
Expert-level understanding of and experience using deep learning tools and approaches (transformer-based encoders/decoders, LLMs, reinforcement learning, etc.) as demonstrated through publications or projects
Hands-on experience leading the building and scaling of deep learning training pipelines on multi-GPU computational infrastructure using PyTorch, Huggingface, and/or other tools
Knowledge of or the ability to learn biological concepts and data types, including the ability to work and communicate effectively with biologists
Excellent verbal and written communication skills; fluent verbal and written English language skills
Experience building agentic workflows (preferred)
Prior experience in pharmaceutical application areas (preferred)

Responsibilities

Apply, adapt, and in some cases create multi-modal foundation models such as large language models (LLMs), diffusion models, and encoder architectures to answer biological domain-specific questions
Address real-world biological modeling challenges such as data sparsity, class imbalance, noise, experimental bias, and heterogeneity of effects
Thoughtful model evaluation that incorporates appropriate benchmarks, statistical tests, and problem understanding to support technical and business decisions
Work in close collaboration with partners across the organization including wet-lab scientists, Research IT, and other computational scientists to broaden the impact of AI developments
Maintain and share up-to-date knowledge of modern advances in the field, including presenting work at public conferences

Skills

Machine Learning

Statistics

Foundation Models

Multi-modal Models

Large Language Models

Cell Engineering

Target Discovery

Predictive Biology

Bristol-Myers Squibb

Develops and delivers biopharmaceutical medicines

About Bristol-Myers Squibb

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, focusing on areas like cancer, autoimmune diseases, and heart conditions. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs, offering affordable alternatives that meet the same quality standards as their branded counterparts. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, enhancing access to healthcare. The company's goal is to improve patient outcomes while maintaining a commitment to sustainability and corporate responsibility.

New York City, New YorkHeadquarters

1887Year Founded

$33,706.1MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

10,001+Employees

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Risks

Increased competition in oncology from emerging biotech firms like ArsenalBio.

BMS's lawsuit over the 340B Drug Pricing Program may lead to regulatory challenges.

Rapid AI and digital tech evolution may pose integration challenges for BMS.

Differentiation

BMS focuses on innovative cancer treatments through collaborations like ArsenalBio for T cell therapies.

The company emphasizes digital health technologies, enhancing clinical trial management and patient engagement.

BMS offers both innovative and generic medicines, increasing affordable healthcare solutions.

Upsides

BMS's partnership with Medidata enhances clinical research processes and patient outcomes.

The collaboration with AI Proteins advances novel miniprotein-based therapeutics, expanding therapeutic modalities.

BMS's global license agreement with BioArctic expands its portfolio in neurodegenerative diseases.

Land your dream remote job 3x faster with AI

Try Jobo Free